Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | RAB9A | P51151 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.66 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.61 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.61 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.61 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.61 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.61 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.61 |
| ▸ | THRB | P10828 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dimethylamine SCHEMBL496581 | 0.94 | SMN1; SMN2 (0.66) | NPC1TSHRRAB9ASMN1; SMN2RXFP1 | |
| SCHEMBL496820 | 0.88 | RXFP1 (0.59) | NPC1TSHRRAB9ASMN1; SMN2RXFP1 | |
| SCHEMBL496814 | 0.84 | MAPT (0.76) | NPC1TSHRRAB9ASMN1; SMN2RXFP1 | |
| SCHEMBL2031649 | 0.84 | RXFP1 (0.55) | NPC1TSHRRAB9ASMN1; SMN2RXFP1 | |
| SCHEMBL2027048 | 0.84 | RXFP1 (0.51) | NPC1TSHRRAB9ASMN1; SMN2RXFP1 | |
| SCHEMBL7956285 | 0.82 | RXFP1 (0.56) | NPC1TSHRRAB9ASMN1; SMN2RXFP1 | |
| SCHEMBL18973345 | 0.82 | RXFP1 (0.56) | NPC1TSHRRAB9ASMN1; SMN2RXFP1 | |
| SCHEMBL2830794 | 0.81 | RXFP1 (0.62) | NPC1TSHRRAB9ASMN1; SMN2RXFP1 | |
| SCHEMBL10878254 | 0.80 | SMN1; SMN2 (0.69) | NPC1TSHRRAB9ASMN1; SMN2RXFP1 | |
| SCHEMBL2023662 | 0.80 | PDE2A (0.57) | NPC1TSHRRAB9ASMN1; SMN2RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1874775-B1 | TRIAZOLOPHTHALAZINES AS PDE2-INHIBITORS | NYCOMED GMBH (DE) | 2012-10-10 | — | — | EP | disclosed |
| EP-1836207-B1 | TRIAZOLOPHTHALAZINES AS PDE2-INHIBITORS | NYCOMED GMBH (DE) | 2012-10-10 | — | — | EP | disclosed |
| US-8106047-B2 | (4-Methoxyphenyl)-[3-(4-methoxyphenyl)-[1,2,4]triazolo[3,4-a]phthalazin-6-yl]-amine; phosphodiesterase inhibitors; septic shock or vascular edema; neoangiogenesis or inflammatory disease | NYCOMED GMBH (DE) | 2012-01-31 | — | — | US | disclosed |
| US-20110136803-A1 | Triazolophthalazines | NYCOMED GMBH (DE) | 2011-06-09 | — | — | US | disclosed |
| US-7851472-B2 | Triazolophthalazines | NYCOMED GMBH (DE) | 2010-12-14 | — | — | US | disclosed |
| US-20100286140-A1 | TRIAZOLOPHTHALAZINES | NYCOMED GMBH (DE) | 2010-11-11 | — | — | US | disclosed |
| EP-1791543-B1 | TRIAZOLOPHTHALAZINES | NYCOMED GMBH (DE) | 2010-06-16 | — | — | EP | disclosed |
| US-7671050-B2 | Triazolophthalazines | NYCOMED GMBH (DE) | 2010-03-02 | — | — | US | disclosed |
| US-7645756-B2 | 6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-[1,2,4]triazolo[4,3-b]pyridazine; has histamine-H3 receptor antagonistic effect or a histamine-H3 receptor inverse-agonistic effect; for metabolic system, circulatory system or nervous system diseases | BANYU PHARMACEUTICAL CO. LTD. (JP) | 2010-01-12 | — | — | US | disclosed |
| US-20090005372-A1 | Triazolophthalazines | ALTANA PHARMA AG (DE) | 2009-01-01 | — | — | US | disclosed |
| EP-1228069-B1 | BICYCLIC AND TRICYCLIC HETEROAROMATIC COMPOUNDS | NEUROGEN CORP (US) | 2003-04-02 | — | — | EP | disclosed |
| US-6511987-B1 | Heterocyclic derivatives that bind to the benzodiazepine site of GABAA receptors for treatment of central nervous system disorders | NEUROGEN CORPORATION | 2003-01-28 | — | — | US | disclosed |
| WO-2002083140-A1 | INHIBITORS OF AKT ACTIVITY | MERCK & CO., INC. (US) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002083064-A2 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 2002-10-24 | — | — | WO | disclosed |
| US-6255305-B1 | PSYCHOLOGICAL DISORDERS | MERCK SHARP & DOHME LIMITED (GB) | 2001-07-03 | — | — | US | disclosed |
| EP-0915875-A2 | SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 1999-05-19 | — | — | EP | disclosed |
| WO-1998004559-A2 | SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 1998-02-05 | — | — | WO | disclosed |
| US-4788186-A | ANXIOLYTIC AGENTS | GRUPPO LEPETIT S.P.A. (IT) | 1988-11-29 | — | — | US | disclosed |
| EP-0085840-B1 | NEW 6-SUBSTITUTED-S-TRIAZOLO(3,4-A)PHTHALAZINE DERIVATIVES | GRUPPO LEPETIT S.P.A. (IT) | 1986-10-01 | — | — | EP | disclosed |
| EP-0085840-A1 | New 6-substituted-s-triazolo(3,4-a)phthalazine derivatives | GRUPPO LEPETIT S.P.A. (IT) | 1983-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286140-A1 | TRIAZOLOPHTHALAZINES | PDE2A, PDE12, PDE3A | NPC1 3556/4885TSHR 1435/4885RAB9A 3017/4885 |
| US-20110136803-A1 | Triazolophthalazines | PDE2A, PDE3A, PDE12 | NPC1 3725/4885TSHR 1052/4885RAB9A 2855/4885 |
| US-20090005372-A1 | Triazolophthalazines | PDE2A, PDE12, PDE3A | NPC1 3556/4885TSHR 1435/4885RAB9A 3017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.